Quantum BioPharma updates Form F-3 references

Quantum BioPharma Ltd. filed an amended Form 6-K/A to update the treatment of a previously furnished August 10, 2026 press release.

Rhea-AI Filing Summary

Quantum BioPharma Ltd. filed an amended Form 6-K/A to update the treatment of a previously furnished August 10, 2026 press release. The amendment’s sole purpose is to furnish that press release again as Exhibit 99.1 and to incorporate it, and the original Form 6-K report, by reference into the company’s Form F-3 registration statement (SEC File No. 333-276264). No new events are reported and the prior disclosures remain unchanged, other than this incorporation-by-reference clarification.

Key Terms

foreign private issuer, Form 6-K/A, incorporated by reference, Registration Statement on Form F-3

4 terms

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 6-K/A regulatory

"FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER"

Form 6-K/A is an amended report filed with the U.S. Securities and Exchange Commission by a foreign (non‑U.S.) company to correct or add material information previously sent in a Form 6‑K. It matters to investors because it updates the official public record—think of it as a corrected or expanded page in a company’s disclosure file—so the new or corrected details can affect how investors judge the company’s risks, results or future prospects.

incorporated by reference regulatory

"Exhibit 99.1 included with this Amendment is hereby incorporated by reference"

Registration Statement on Form F-3 regulatory

"into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264)"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Quantum BioPharma (QNTM) doing in this Form 6-K/A amendment?

Quantum BioPharma filed this Form 6-K/A solely to re-furnish its August 10, 2026 press release as Exhibit 99.1 and to have that press release incorporated by reference into its Form F-3 registration statement.

Does this Quantum BioPharma (QNTM) Form 6-K/A report any new business events?

No. The amendment states it does not modify or update the disclosures in the original August 10, 2026 report, and does not reflect events occurring after that original submission date, beyond the incorporation-by-reference change.

How does this Form 6-K/A affect Quantum BioPharma’s (QNTM) Form F-3 registration?

The amendment specifies that Exhibit 99.1, the August 10, 2026 press release, is now incorporated by reference into Quantum BioPharma’s Form F-3 registration statement (SEC File No. 333-276264), making it part of that registration.

What document is incorporated by reference for Quantum BioPharma (QNTM) in this filing?

The document is the press release dated August 10, 2026, designated as Exhibit 99.1. It, along with the original Form 6-K report, is incorporated by reference into the Form F-3 registration statement.

Who signed Quantum BioPharma’s (QNTM) Form 6-K/A amendment and in what capacity?

The amendment was signed on behalf of Quantum BioPharma Ltd. by Donal Carroll, who is identified as the company’s Chief Financial Officer, acting as the duly authorized signatory under the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 11:07 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

(Amendment No. 1)

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-39152

QUANTUM BIOPHARMA LTD.

(Registrant)

1 Adelaide Street East, Suite 801

Toronto, Ontario M5C 2V9

(Address of Principal Executive Offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On August 10, 2026, Quantum BioPharma Ltd. (the “Company”) furnished a report on Form 6-K, Accession No. 0001171843-26-005370 (the “Original Report”), which included as Exhibit 99.1 a press release dated August 10, 2026 (the “Press Release”). This Amendment No. 1 to the Original Report is being furnished solely to furnish the Press Release as Exhibit 99.1 and to incorporate the contents of the Original Report, including Exhibit 99.1, into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264).

Except as specifically described in this explanatory note, this Amendment does not reflect events that may have occurred subsequent to the original submission date and does not modify or update in any way the disclosures made in the Original Report.

1

DOCUMENTS INCORPORATED BY REFERENCE

Exhibit 99.1 included with this Amendment is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264) and shall be deemed to be a part thereof from the date on which the Original Report was furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 13, 2026	QUANTUM BIOPHARMA LTD. (Registrant)
	By	/s/ Donal Carroll
		Donal Carroll
		Chief Financial Officer

3

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated August 10, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished August 10, 2026, Accession No. 0001171843-26-005370)

4